E. V. Bezumova

E. V. Bezumova

Auto-generated profile, based on publicly available information

E. V. Bezumova

N.N. Blokhin National Medical Research Center of Oncology

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2024 in Journal of oncology: diagnostic radiology and radiotherapy
Verified
Journal Article
Closed access
VIV. S. Ilyakov
V. S. Ilyakov
APA. I. Pronin
A. I. Pronin
APA. V. Parnas
A. V. Parnas
ASA. S. Subbotin
A. S. Subbotin
AKA. S. Krylov
A. S. Krylov
VMV. B. Matveev
V. B. Matveev
Introduction: Attempts have been made to use various RPs, other than 18F-FDG in the diagnostics of renal cell carcinoma (RCC), with promising results demonstrated by PSMA-specific RPs, in particular 18F-PSMA-1007.A prospective study was conducted at N.N. Blokhin NMRCO to establish capabilities of PET/CT with 18F-FDG and 18F-PSMA-1007 in primary and recurrent ccRCC diagnostics.Material and methods: Forty-eight patients were included in the study, 28 with renal masses and 20 with suspected local recurrence of ccRCC. Biopsy results were available in all patients. All patients underwent PET/CT with 18F-PSMA-1007 and 18F-FDG.Results: Thirty-nine renal neoplasms were identified in 28 patients. 24 of 39 foci (21 patients) were PSMA-positive and 18 of 39 foci (16 patients) were FDG-positive. No false-positive foci were identified. The sensitivity, specificity, positive and negative predictive value in primary RCC were: for 18F-PSMA-1007 — 75, 100, 100 and 85 %, respectively; for 18FDG — 57, 100, 100 and 76 %, respectively. The SUVmax level of 18F-PSMA-1007 exceeded 18FDG in 27 of 28 patients (38 foci); the tumor/background ratio was higher in 16 of 28 patients (24 foci). Tumor thrombosis was detected in 6 patients (PSMA-positive 6 of 6, FDG-positive 5 of 6). PSMA-SUVmax levels in thrombi exceeded 18FDG in all patients, tumor/background ratio in 5 out of 6 patients. Local recurrence was detected in 13 of 20 patients (27 foci). 10 foci in the remaining 7 patients were considered as false positives. No false-negative results were obtained. Sensitivity, specificity, positive and negative predictive value in the diagnosis of local recurrence of ccPCC: 18F-PSMA-1007 — 100, 94, 81 and 100 %, respectively; 18FDG -100, 89, 68 and 100 %, respectively.SUVmax and tumor/background ratio were found to correlate with primary tumor and recurrent node sizes for both RPs.Discussion and conclusions: At the moment, the role of 18F-PSMA-1007 in RCC diagnostics has not been defined. We can note the high efficiency of this RP in the assessment of the primary focus and recurrence of ccRCC, its usage is justified in cases, when routine diagnostic methods do not give an unambiguous answer.The possibilities of 18F-PSMA-1007 in metastatic ccRCC diagnostics are of the greatest interest. A significant prospective material has been collected in our department, which will be the basis for further study of this RP in the diagnostics of metastatic ccRCC.

19 September 2024 in Journal of oncology: diagnostic radiology and radiotherapy
Verified
Journal Article
Open access
PDF file
VIV. S. Ilyakov
V. S. Ilyakov
APA. I. Pronin
A. I. Pronin
APA. V. Parnas
A. V. Parnas
ASA. S. Subbotin
A. S. Subbotin
AKA. S. Krylov
A. S. Krylov
VMV. B. Matveev
V. B. Matveev
Purpose: To demonstrate the capabilities of PET/CT with 18F-PSMA-1007 in comparison with 18F-FDG in the diagnostics of metastatic ccRCC.Material and methods: Ninety-seven patients with metastatic ccRCC were included in the study. Biopsy results of the primary tumor were available in all patients. Metastatic foci were confirmed by biopsy, follow-up and other diagnostic methods. All patients under went PET/CT with 18F-PSMA-1007 and 18F FDG.Results: A total of 1247 metastases were identified in 97 patients: 1002 — PSMA-positive, 245 — PSMA-negative, 694 — FDG-positive, and 553 — FDG-negative. The largest number of foci was found in the lungs (601 in 43 patients), bones (220 in 46 patients), and lymph nodes (166 in 34 patients).Sixty-two patients had more PSMA-positive foci compared with 18FDG, 32 had an equal number of foci, and 3 had more foci according to PET/CT with 18FDG.The sensitivity and specificity of 18F-PSMA-1007 in the diagnostics of ccRCC metastases were 80 % and 72 %, positive and negative predictive value were 87 % and 61 %, respectively.The sensitivity and specificity of 18F-FDG in the diagnostics of ccRCC metastases were 55 % and 54 %, positive and negative predictive value were 69 % and 41 %, respectively.The mean SUVmax difference between 18F-PSMA-1007 and 18FDG was 5.32, and the mean TBR difference was 5.66. Lung foci demonstrated significantly lower SUVmax and TBR for both RPs compared to other metastases.Discussion and conclusions. Data analysis demonstrates higher efficiency of 18F-PSMA-1007 compared to 18F-FDG in the diagnostics of ccRCC metastases. PET/CT with 18F-PSMA-1007 revealed a higher number of metastases, SUVmax and TBR in studies with 18F-PSMA-1007 are on average significantly higher than those with 18F FDG.PET/CT with 18F-PSMA-1007 demonstrates the lowest efficiency in the diagnosis of foci in the lungs up to 1 cm. It is feasible to analyze pulmonary foci and other metastases separately to exclude the influence of a large number of low-active and false-negative foci on statistical parameters.PET/CT with 18F-PSMA-1007 can be recommended for use in patients with suspected metastatic ccRCC as an alternative to routine diagnostic methods and PET/CT with 18F-FDG. The potential of 18F-PSMA-1007 in assessing the efficacy of systemic therapy requires further investigation.

20 April 2024 in Radiatsionnaya Gygiena = Radiation Hygiene
Verified
Journal Article
Open access
PDF file
APA. V. Petryakova
A. V. Petryakova
LCL. A. Chipiga
L. A. Chipiga
GAG. A. Andreev
G. A. Andreev
EGE. A. Gromova
E. A. Gromova
GKG. V. Kataeva
G. V. Kataeva
EBE. V. Bezumova
E. V. Bezumova
The usage of modern positron emission tomography scanners, in particular with digital detectors, allows obtaining images with better quality, increases the detection of small pathological lesions, reduces scanning time and the activity administered to the patient which leads to a decrease of patient dose as well. However, the values of the quantitative image parameters shift upward, which can lead to significant differences with the quantitative assessment obtained on the previous generation device. In order to compare quantitative assessments obtained on different generations of PET/CT, it is necessary to harmonise quantitative image parameters and perform regular quality control. The aim of current work is the comparison of different methods for harmonization of quantitative image parameters on the example of harmonisation of two PET/CT: Biograph mCT 128 and Biograph Vision 600. NEMA IEC Body phantom filled with 18F solution was scanned in Listmode in two bed positions with overlap in the sphere area during five minutes per bed position. Recovery coefficient used for harmonisation was measured for each sphere of the phantom. Harmonisation between Vision and mCT was performed using two methods: choosing of harmonised reconstruction parameters and EQ.PET technology. The acceptable divergence range between the recovery coefficients for Vision and for mCT is ±10% (20% range). The recovery coefficients measured for reconstruction: 4 iterations and 5 subsets, ToF+PSF, Gaussian 7 mm, matrix 220x220 completely fit within the 20% range. The recovery coefficients measured using EQ = 6 mm (optimal value) fit within the 20% range except the spheres with a diameter of 10 and 13 mm. Both harmonisation methods allow to approximate the quantitative assessment/ However, EQ.PET has limitations for the small lesions. Choosing harmonised reconstruction parameters is the mostwidely used harmonisation method; the EQ.PET allows to harmonise quantitative assessment without the use of multiple reconstruction protocols and losses in visualization ability

21 May 2026 in The EANM Journal
Verified
Journal Article
Open access
ANA. Nikiforuk
A. Nikiforuk
AKA. Khalimon
A. Khalimon
ASA. Shakirova
A. Shakirova
ALA. Lokhova
A. Lokhova
VBV. Bagaturya
V. Bagaturya
EBE. Bezumova
E. Bezumova